Form 4: Blueprint Medicines Director Alexis Borisy Granted 3,902 Restricted Stock Units

Blueprint Medicines Corporation's Director, Alexis Borisy, has been granted 3,902 restricted stock units (RSUs) valued at $128.12 per share, increasing his beneficial ownership to 78,062 shares.

Summary

• Alexis Borisy, a Director at Blueprint Medicines Corporation (BPMC), received a grant of 3,902 restricted stock units (RSUs).
• The transaction occurred on June 18, 2025, with each RSU valued at $128.12.
• Following this grant, Mr. Borisy's total beneficial ownership in Blueprint Medicines Common Stock stands at 78,062 shares.
• The RSUs are set to vest 100% on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their stake in the company through an RSU grant, which aligns their interests with shareholders and signals confidence in future performance.

Positives

• The acquisition of additional shares by a director, even through an RSU grant, can signal confidence in the company's future prospects from an insider's perspective.
• The transaction was executed under a Rule 10b5-1(c) plan, which suggests a pre-planned and systematic approach to equity compensation or investment.

Future Outlook

The document indicates a future vesting event for the granted restricted stock units, which will occur on the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders.

Industry Context

NA

Stakeholder Impact

• Shareholders: The RSU grant to a director may be viewed positively as it aligns management's incentives with shareholder value creation and signals insider confidence.
• Employees: While not directly impacting all employees, equity grants to leadership can set a precedent for compensation structures and reinforce a culture of shared ownership.

Next Steps

• Vesting of the 3,902 restricted stock units on the earlier of June 18, 2026, or the next annual meeting of Blueprint Medicines' stockholders.

Key Dates

Recommendation

Keywords

Blueprint Medicines, BPMC, Alexis Borisy, Restricted Stock Units, RSU Grant, Insider Transaction, SEC Form 4, Director Compensation, Equity Compensation, Biotechnology, Pharmaceuticals